Treatment for Chronic hepatitis B patients with low viral load prevents liver damage.

Study to assess the effectiveness of the treatment in chronic hepatitis patients with low viremia and evaluate strategies to optimize intervention - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105288

Enrollment

100

Registered

2026-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B181- Chronic viral hepatitis B withoutdelta-agent

Interventions

Intervention1: Tenofovir: Dose: 300 mg per day for 1 year to be taken orally. Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: HBV DNA 2000 to 20000 Elevated ALT above 30IU in males and 19 IU in females.

Exclusion criteria

Exclusion criteria: Exclusion criteria include prior HBV antiviral therapy, HCC, co-infection with HIV/HCV, other liver diseases (e.g., autoimmune hepatitis, Wilson s disease), pregnancy, lactation, serious comorbidities, or inability to consent.

Design outcomes

Primary

Measure	Time frame
Change in the quantitative HbsAg, HbV DNA from baseline to 12 months.Timepoint: Change in the quantitative HbsAg, HbV DNA from baseline to 12 months.	—

Secondary

Measure	Time frame
Liver fibrosisTimepoint: 6, 12 months	—

Countries

India

Contacts

Public ContactAnindita Banerjee

ICMR-National Institute of Immunohaematology

anny.banerjee@gmail.com9830476354

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026